When the research into stem cell treatment made promising initial scientific findings, it gained a lot of attention across the country. The researchers planned to bring the usage of stem cells into the mainstream and begin a wave of stem-cell projects aimed at treating various conditions, such as Alzheimer’s and Parkinson’s disease. Unfortunately, the scientific community and medical associations haven’t really backed the research yet, but Jason Hope, a renowned philanthropist, entrepreneur and anti-aging expert, thinks the research has a huge potential, especially with the right approach.
The Great Breakthrough
More than two decades ago, a group of scientists managed to extract human embryonic stem cells and develop them in a lab. Their ability to grow “parent” cells that can facilitate the development of new cells in the human body was remarkable as it would make it possible to create effective treatments for neurodegenerative conditions.
Jason Hope’s Ideas and Involvement
Hope, who has always dedicated a lot of resources to medical research, maintains that stem cell treatments will always be considered experimental until they go through the right research and rigorous testing. As an anti-aging treatment professional, he asserts that it’s very easy for people to be skeptical of a company when it makes lofty claims or promotes faulty or unverified treatments.
Nonetheless Hope acknowledges the potential of maximizing stem cell therapies, and that’s why he’s actively involved in extensive research to come up with stem cell treatments safely and ethically. For example, he has been backing Strategies for Engineered Negligible Senescence (SENS) (Biotechnology1).
This is an organization that conducts research into potential preventative treatments for neurodegenerative conditions. According to him, the organization has already made significant steps in developing effective treatments for Parkinson’s disease.
Besides being an active philanthropist and entrepreneur, Hope is a professional in longevity and anti-aging treatments, and he has a strong affinity for the advancement of biomedicine. He’s also involved in various scientific organizations and actively invests in startups.